邻甲基苯乙胺盐酸盐 | 55755-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻甲基苯乙胺盐酸盐
• 英文名称: 2-(2-methylphenyl)ethan-1-amine hydrochloride
• 英文别名: 2-methyl-phenethylamine; hydrochloride；2-Methyl-phenaethylamin; Hydrochlorid；[2-(2-methylphenyl)ethyl]amine hydrochloride；2-Methylphenethylamine hydrochloride；2-(2-methylphenyl)ethanamine;hydrochloride
• CAS: 55755-18-5
• 化学式: C₉H₁₃N*ClH
• mdl: MFCD21647853
• 分子量: 171.67
• InChiKey: DQLZLKLLQGKKFR-UHFFFAOYSA-N

物化性质

• 熔点：
  143 - 146?C
• 溶解度：
  可溶于乙腈（少许）、氯仿（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  邻甲基苯乙胺盐酸盐 、 二聚氰胺 生成 N-1-(2-methyl)phenethylbiguanide hydrochloride
  参考文献：
  名称：

  Optimization of First-in-Class Dual-Acting FFAR1/FFAR4 Allosteric Modulators with Novel Mode of Action

  摘要：

  DOI：

  10.1021/acsmedchemlett.2c00160

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• HOMOCYSTEINE SYNTHASE INHIBITOR
  申请人：Nakao Akira

  公开号：US20110034440A1

  公开（公告）日：2011-02-10

  The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.

  本发明提供了一种同型半胱氨酸合酶抑制剂，可用于预防或治疗涉及同型半胱氨酸合酶的疾病。该同型半胱氨酸合酶抑制剂是公式(I)的化合物，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物。
• [EN] SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS DE SQUARAMIDE UTILISÉS EN TANT QUE MODULATEURS ALLOSTÉRIQUES CB1
  申请人：RES TRIANGLE INST

  公开号：WO2023235548A1

  公开（公告）日：2023-12-07

  Squaramide-based cannabinoid 1 receptor (CB1R) allosteric modulators are described. Exemplary analogs may provide improved potencies and pharmacokinetic properties. Methods of using the analogs to treat diseases mediated by CB1R, such as substance abuse and obesity, are described.

  本文介绍了基于水杨酰胺的大麻素 1 受体（CB1R）异位调节剂。示例性类似物可提供更好的效力和药代动力学特性。描述了使用类似物治疗由 CB1R 介导的疾病（如药物滥用和肥胖症）的方法。
• US8513235B2
  申请人：——

  公开号：US8513235B2

  公开（公告）日：2013-08-20
• [EN] N-BIPHENYLMETHYLINDOLE MODULATORS OF PPARG<br/>[FR] MODULATEURS N-BIPHÉNYLMÉTHYLINDOLE DE PPARG
  申请人：KAMENECKA THEODORE MARK

  公开号：WO2012170554A1

  公开（公告）日：2012-12-13

  The invention provides molecular entities that bind with high affinity to PPARG (PPARƴ), inhibit kinase-mediated, e.g., cdk5-mediated, phosphorylation of PPARG, but do not exert an agonistic effect on PPARG. Compounds of the invention can be used for treatment of conditions in patients wherein PPARG plays a role, such as diabetes, insulin resistance, impaired glucose tolerance, prediabetes, hyperglycemia, hyperinsulinemia, obesity, or inflammation. In methods of treatment of these conditions using a compound of the invention, the compound can avoid producing side effects of significant weight gain, edema, impairment of bone growth or formation, or cardiac hypertrophy, or any combination thereof, in the patient receiving the compound. Methods of preparation of the compounds, bioassay methods for evaluating compounds of the invention as non-agonistic PPARG binding compounds, and pharmaceutical compositions are also provided.